A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients.

Trial Profile

A Randomized, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV Versus LPV/RTV in Treatment-Experienced HIV-1 Infected Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2015

At a glance

  • Drugs Darunavir (Primary) ; Lopinavir/ritonavir; Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Ritonavir
  • Indications HIV-1 infections
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms TITAN
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 01 Dec 2011 Additional location (Ireland) added as reported by ClinicalTrials.gov.
    • 01 Dec 2011 Additional location (Ireland) added as reported by ClinicalTrials.gov.
    • 01 Dec 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top